| Titolo | Fase | Stato | Sede patologia | Strutture coinvolte | Dettaglio |
A RANDOMIZED PHASE II STUDY TO EVALUATE THE SAFETY AND EFFICACY OF TRASTUZUMAB DERUXTECAN VERSUS CDK4/6 INHIBITOR-BASED ENDOCRINE THERAPY AS FIRST-LINE THERAPY OF HR-POSITIVE AND HER2-LOW/ULTRALOW ADVANCED BREAST CANCER PATIENTS CLASSIFIED AS NON-LUMINAL SUBTYPE ACCORDING TO GENE EXPRESSION PROFILING (THE PONTIAC STUDY). |
II |
in corso |
Carcinoma mammario |
- SC Oncologia Clinica Sperimentale di Senologia |
|
: Studio di fase 3, randomizzato, in aperto, che valuta la terapia di combinazione con avutometinib più defactinib rispetto al trattamento scelto dallo sperimentatore in pazienti affette da carcinoma ovarico sieroso di basso grado (LGSOC) ricorrente (RAMP 301) |
III |
in corso |
CARCINOMA OVARICO |
- SC Oncologia Clinica Sperimentale Uro - Ginecologica |
|
A PHASE II, OPEN-LABEL, MULTICENTER STUDY TO EVALUATE THE OPTIMIZATION OF THE CYTOKINE RELEASE SYNDROME PROFILE FOR GLOFITAMAB IN COMBINATION WITH GEMCITABINE PLUS OXALIPLATIN IN PATIENTS WITH RELAPSED/REFRACTORY DIFFUSE LARGE B-CELL LYMPHOMA |
II |
in corso |
Linfoma diffuso a grandi cellule B |
- SC Ematologia Oncologica |
|
A PHASE IB DOSE ESCALATION AND PHASE II DOSE OPTIMIZATION, RANDOMIZED, OPEN-LABEL, MULTICENTER TRIAL OF ORAL ZONGERTINIB (BI 1810631) IN COMBINATION WITH INTRAVENOUS TRASTUZUMAB DERUXTECAN (T-DXD) OR IN COMBINATION WITH INTRAVENOUS TRASTUZUMAB EMTANSINE (T-DM1) FOR TREATMENT OF PATIENTS WITH ADVANCED HER2+ METASTATIC BREAST CANCER (MBC) AND METASTATIC GASTRIC, GASTROESOPHAGEAL JUNCTION, OR ESOPHAGEAL ADENOCARCINOMA (MGEAC) |
I/II |
in corso |
CARCINOMA MAMMARIO; GASTRICO; ESOFAGICO |
- SC Sperimentazioni Cliniche |
|
COMPLICANZE POST-OPERATORIE E ABITUDINE TABAGICA IN CHIRURGIA COLORETTALE (STUDIO PASSAGE). UNO STUDIO MULTICENTRICO OSSERVAZIONALE PROSPETTICO E RETROSPETTIVO IN ITALIA |
NA |
in corso |
cancro colonrettale |
- SC Chirurgia Oncologica Colon - Rettale |
